PALO ALTO, Calif.--(BUSINESS WIRE)--Open Monoclonal Technology, Inc. (OMT) today announced a license that provides Celgene Corporation (Celgene) with unlimited access to OMT’s proprietary OmniRat®, OmniMouse® and OmniFlic™ platforms for generation of human antibody therapeutics.
Dr. Roland Buelow, founder and CEO of OMT, commented, “Celgene is a global leader in novel therapies for cancer and inflammatory diseases where human therapeutic antibodies are particularly useful. The company will become OMT’s 11th partner with unlimited platform access. OMT will facilitate rapid and efficient technology integration into Celgene and believes it will be enabling for the company’s growing pipeline of antibody therapeutics.”
About Open Monoclonal Technology, Inc.
Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for generation of human therapeutic antibodies, naturally optimized human antibodies®, and the only company in the world with four transgenic animal platforms, jointly OmniAb™.
OmniRat® is the industry’s first human monoclonal antibody technology based on rats. It has a complete immune system with a diverse antibody repertoire and generates antibodies with human idiotypes as well as wild-type animals make rat antibodies. OmniMouse® is a transgenic mouse that complements OmniRat and expands epitope coverage. OmniFlic™ is an engineered rat with a fixed light chain for development of bispecific, fully human antibodies. UniRat™ is the first transgenic rat generating fully human heavy chain-only antibodies and nanobodies for polyspecific applications.
All four OmniAb™ platforms deliver human antibodies with high affinity, specificity, expression, solubility and stability. They use patented technology, have broad freedom to operate and are available worldwide for all targets and indications. Current partners include Celgene, Chugai, Genmab, Genentech, HanAll, Janssen, Merck KGaA, Pfizer, Roche, Symphogen, an undisclosed global pharmaceutical company and several smaller biotech companies and universities. OmniAb antibody discovery services are available via Antibody Solutions in the US, Aldevron in Germany and WuXi AppTec in China.
For more information, please visit www.omtinc.net.